Prime Medicine (PRME) FCF Margin (2024 - 2026)

Prime Medicine (PRME) has 3 years of FCF Margin data on file, last reported at 4989.49% in Q1 2026.

• Quarterly FCF Margin fell 146273.0% year-over-year to 4989.49% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3929.75% (down 115393.0% YoY) and the FY2025 annual result came in at 3607.41%, up 55012.0% from the prior year.
• FCF Margin slipped to 4989.49% in Q1 2026, from 4480.43% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 696.38% in Q4 2024 to a low of 11597.29% in Q1 2024.
• A 3-year average of 5128.92% and a median of 4003.59% in 2025 frame the typical range for FCF Margin.
• The widest YoY moves for FCF Margin: up 807054 bps in 2025, down 517681 bps in 2025.
• Tracing PRME's FCF Margin over 3 years: stood at 696.38% in 2024, then tumbled by 743 bps to 4480.43% in 2025, then dropped by 11 bps to 4989.49% in 2026.
• The last three FCF Margin figures came in at 4989.49% (Q1 2026), 4480.43% (Q4 2025), and 3194.45% (Q3 2025), per Business Quant data.